These results indicate that RUNX2 plays a critical role in the CAF/BMP2-induced osteomimicry of breast cancer cells, which obtain multidrug resistance in both tumor and bone microenvironments, and that RUNX2 depletion efficiently abolishes these effects. The gene discussed is BMP2; the disease is breast carcinoma.